Ampio Pharmaceuticals Past Earnings Performance
Past criteria checks 0/6
Ampio Pharmaceuticals's earnings have been declining at an average annual rate of -28.9%, while the Pharmaceuticals industry saw earnings growing at 12.9% annually.
Key information
-28.9%
Earnings growth rate
-22.8%
EPS growth rate
| Pharmaceuticals Industry Growth | 7.3% |
| Revenue growth rate | n/a |
| Return on equity | -163.7% |
| Net Margin | n/a |
| Last Earnings Update | 30 Sep 2023 |
Recent past performance updates
No updates
Recent updates
Revenue & Expenses BreakdownBeta
How Ampio Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 23 | 0 | -9 | 8 | 2 |
| 30 Jun 23 | 0 | -14 | 10 | 4 |
| 31 Mar 23 | 0 | -15 | 12 | 6 |
| 31 Dec 22 | 0 | -16 | 11 | 9 |
| 30 Sep 22 | 0 | -20 | 14 | 13 |
| 30 Jun 22 | 0 | -18 | 12 | 13 |
| 31 Mar 22 | 0 | -19 | 10 | 13 |
| 31 Dec 21 | 0 | -17 | 9 | 12 |
| 30 Sep 21 | 0 | -15 | 6 | 9 |
| 30 Jun 21 | 0 | -15 | 6 | 8 |
| 31 Mar 21 | 0 | -14 | 6 | 7 |
| 31 Dec 20 | 0 | -16 | 7 | 9 |
| 30 Sep 20 | 0 | -12 | 7 | 13 |
| 30 Jun 20 | 0 | -16 | 7 | 14 |
| 31 Mar 20 | 0 | -13 | 7 | 15 |
| 31 Dec 19 | 0 | -14 | 6 | 13 |
| 30 Sep 19 | 0 | -11 | 5 | 9 |
| 30 Jun 19 | 0 | 2 | 4 | 6 |
| 31 Mar 19 | 0 | 6 | 4 | 6 |
| 31 Dec 18 | 0 | 34 | 4 | 7 |
| 30 Sep 18 | 0 | -11 | 5 | 9 |
| 30 Jun 18 | 0 | -21 | 5 | 10 |
| 31 Mar 18 | 0 | -28 | 5 | 11 |
| 31 Dec 17 | 0 | -52 | 5 | 10 |
| 30 Sep 17 | 0 | -12 | 5 | 9 |
| 30 Jun 17 | 0 | -12 | 6 | 8 |
| 31 Mar 17 | 0 | -14 | 6 | 8 |
| 31 Dec 16 | 0 | -19 | 7 | 11 |
| 30 Sep 16 | 0 | -22 | 8 | 13 |
| 30 Jun 16 | 0 | -23 | 8 | 15 |
| 31 Mar 16 | 0 | -24 | 9 | 16 |
| 31 Dec 15 | 0 | -22 | 9 | 15 |
| 30 Sep 15 | 0 | -26 | 9 | 18 |
| 30 Jun 15 | 0 | -30 | 11 | 21 |
| 31 Mar 15 | 0 | -33 | 11 | 23 |
| 31 Dec 14 | 0 | -30 | 9 | 22 |
| 30 Sep 14 | 0 | -36 | 12 | 25 |
| 30 Jun 14 | 0 | -32 | 10 | 23 |
| 31 Mar 14 | 0 | -30 | 9 | 22 |
| 31 Dec 13 | 0 | -24 | 7 | 17 |
| 30 Sep 13 | 0 | -20 | 6 | 14 |
| 30 Jun 13 | 0 | -17 | 6 | 12 |
| 31 Mar 13 | 0 | -13 | 4 | 9 |
| 31 Dec 12 | 0 | -12 | 6 | 6 |
Quality Earnings: APH is currently unprofitable.
Growing Profit Margin: APH is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: APH is unprofitable, and losses have increased over the past 5 years at a rate of 28.9% per year.
Accelerating Growth: Unable to compare APH's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: APH is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (2.8%).
Return on Equity
High ROE: APH has a negative Return on Equity (-163.68%), as it is currently unprofitable.